2019
DOI: 10.2147/jaa.s223093
View full text
|
|
Share

Abstract: IntroductionFluticasone furoate (FF)/vilanterol (VI) dry powder inhaler (DPI) is the only once-daily maintenance inhaled corticosteroid (ICS)/long-acting β2 adrenergic agonist (LABA) combination for asthma. We aimed to compare the clinical effects of once-daily FF/VI and twice-daily budesonide (BUD)/formoterol (FM) DPI in patients with controlled stable asthma.MethodsWe performed a randomized crossover trial in which stable asthmatic patients controlled on ICS/LABA received 8 weeks of FF/VI (100/25 μg 1 puff o…

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
1
0

Publication Types

Select...

Relationship

0
0

Authors

Journals